GlobeNewswire
-
20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
16/11/2026 -
ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
16/11/2026 -
Glass House Brands Reports Third Quarter 2026 Financial Results
16/11/2026 -
Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
16/11/2026 -
InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
16/11/2026 -
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
16/11/2026 -
Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/11/2026 -
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
16/11/2026 -
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
16/11/2026 -
Carlsmed to Participate in Upcoming Investor Conferences
16/11/2026 -
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
16/11/2026 -
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
16/11/2026 -
Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly
16/11/2026 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/11/2026 -
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
16/11/2026 -
Exicure Announces Filing of Notification of Late Filing on Form 12b-25
16/11/2026 -
Galimedix Therapeutics outlines development plans in Alzheimer's disease at CTAD 2026
16/11/2026 -
NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026
16/11/2026 -
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
16/11/2026
Pages